I-2-Fluoro-5-Formylbenzonitrile CAS 218301-22-5 Ubunyulu ≥98.0% I-Olaparib Intermediate Factory
Ukucoceka okuphezulu, iMveliso yoRhwebo
I-Olaparib kunye nabaPhakathi abaNxulumeneyo:
Olaparib CAS 763113-22-0
2-Fluoro-5-Formylbenzonitrile CAS 218301-22-5
I-2-Fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoic acid CAS 763114-26-7
1-(Cyclopropylcarbonyl)piperazine Hydrochloride CAS 1021298-67-8
3-Oxo-1,3-Dihydroisobenzofuran-1-Ylphosphonic Acid CAS 61260-15-9
| Igama leMchiza | 2-Fluoro-5-Formylbenzonitrile |
| Izithethantonye | 3-Cyano-4-Fluorobenzaldehyde |
| Inombolo yeCAS | 218301-22-5 |
| Inombolo yeCAT | RF-PI451 |
| Ubume beStokhwe | Kwi-Stock, iMveliso yoMveliso ukuya kwiiToni |
| Ifomula yeemolekyuli | C8H4FNO |
| Ubunzima beMolekyuli | 149.12 |
| Indawo yokunyibilika | 80.0 ukuya 84.0℃ (lit.) |
| Ukunyibilika | Inyibilika kwiMethanol |
| Uphawu | Ruifu Chemical |
| Into | Iinkcukacha |
| Imbonakalo | Mthubi ukuya kwiPowder e-Off-mhlophe |
| Ubunyulu | ≥98.0% |
| Ukufuma (KF) | ≤0.50% |
| Ukungcola ngokupheleleyo | ≤2.0% |
| Umgangatho woVavanyo | Umgangatho woShishino |
| Ukusetyenziswa | Phakathi kwe-Olaparib (CAS: 763113-22-0) PARP-Inhibitor |
Iphakheji: Ibhotile, ingxowa yefoyile yeAluminiyam, Igubu lekhadibhodi, 25kg/Igubu, okanye ngokwemfuno yomthengi.
Imeko yoGcino:Gcina kwizikhongozeli ezivaliweyo kwindawo epholileyo neyomileyo;Khusela ukukhanya kunye nokufuma.
I-2-Fluoro-5-Formylbenzonitrile (i-CAS: 218301-22-5) isetyenziselwa ukulungiswa kwee-heterocyclic compounds njenge-PARP inhibitors yokusetyenziswa kwezonyango.I-2-Fluoro-5-Formylbenzonitrile isetyenziswe njengendawo ephakathi kwe-Olaparib (CAS: 763113-22-0).I-Olaparib yi-molecule encinci inhibitor ye-PARP1 / PARP2 (IC50: 5/1 nM) kodwa ayisebenzi kangako kwi-PARP tankyrase-1 (IC50: 1.5 µM).I-Olaparib (AZD-2281, igama lokurhweba iLynparza) lunyango olujoliswe kwi-FDA oluvunyiweyo lomhlaza, oluphuhliswe yi-KuDOS Pharmaceuticals kwaye kamva yi-AstraZeneca.I-PARP inhibitor, inhibiting i-poly ADP ribose polymerase (PARP), i-enzyme ebandakanyekayo ekulungiseni i-DNA.Isebenza ngokuchasene nomhlaza kubantu abane-hereditary BRCA1 okanye i-BRCA2 yeenguqu, ezibandakanya ezinye ze-ovarian, isifuba, kunye ne-prostate cancer.NgoDisemba 2014, i-olaparib yavunywa ukuba isetyenziswe njenge-arhente enye yi-EMA kunye ne-FDA.Imvume ye-FDA ikwintsholongwane ye-BRCA eguqulweyo (gBRCAm) umhlaza wesibeleko osele ufumene imigca emithathu okanye ngaphezulu yangaphambili yechemotherapy.
